Get the Stockscreener App
0.00
100.00%
-0.1815
After Hours:
.17
0.17
+
Affimed N V stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
See More
Previous Close:
$0.1815
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$2.13M
Revenue:
$19.91M
Net Income/Loss:
$-127.11M
P/E Ratio:
0.00
EPS:
-8.428
Net Cash Flow:
$-132.44M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.505
Affimed N V Stock (AFMD) Company Profile
Compare AFMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
0.00 | 2.13M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-12-22 | Initiated | H.C. Wainwright | Buy |
| Oct-10-22 | Downgrade | Stifel | Buy → Hold |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-23-22 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-21 | Initiated | Truist | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Aug-12-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-19-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Dec-10-15 | Initiated | Laidlaw | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Sep-09-15 | Initiated | Jefferies | Hold |
| Aug-06-15 | Reiterated | Oppenheimer | Outperform |
| Jun-22-15 | Reiterated | Jefferies | Buy |
View All
Affimed N V Stock (AFMD) Latest News
What earnings revisions data tells us about Affimed N.V.July 2025 Opening Moves & Short-Term High Return Ideas - Newser
Automated trading signals detected on Affimed N.V.2025 Retail Activity & High Return Stock Watch Alerts - Newser
Price momentum metrics for Affimed N.V. explainedJuly 2025 Highlights & Entry Point Confirmation Signals - Newser
What MACD and RSI say about Affimed N.V.Chart Signals & Comprehensive Market Scan Reports - Newser
How to build a dashboard for Affimed N.V. stockLong Setup & Fast Entry and Exit Trade Plans - Newser
Intraday pattern recognizer results for Affimed N.V.2025 Price Targets & Smart Allocation Stock Reports - Newser
Sentiment analysis tools applied to Affimed N.V.2025 Top Gainers & Fast Entry Momentum Alerts - Newser
Affimed N.V. stock outlook for YEAR2025 Major Catalysts & Fast Exit and Entry Strategy Plans - Newser
Forecasting Affimed N.V. price range with options data2025 Biggest Moves & Free Safe Capital Growth Stock Tips - Newser
How to recover losses in Affimed N.V. stockWeekly Profit Analysis & AI Enhanced Trading Alerts - Newser
Heatmap analysis for Affimed N.V. and competitorsGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Why Affimed N.V. stock attracts strong analyst attentionJuly 2025 Weekly Recap & Capital Efficiency Focused Strategies - Newser
How Affimed N.V. stock performs during market volatilityJuly 2025 Institutional & Momentum Based Trading Signals - thegnnews.com
Real time breakdown of Affimed N.V. stock performance2025 Price Targets & Expert Curated Trade Setup Alerts - Newser
Ranking Affimed N.V. among high performing stocks via toolsWeekly Market Summary & Real-Time Volume Triggers - Newser
Price action breakdown for Affimed N.V.Weekly Investment Recap & Intraday High Probability Setup Alerts - Newser
Is Affimed N.V. exposed to currency risksMarket Performance Recap & Community Verified Watchlist Alerts - thegnnews.com
Has Affimed N.V. Stock Ever Crashed Historical Volatility Review2025 Trading Recap & Reliable Breakout Stock Forecasts - Newser
Will Affimed N.V. benefit from current market trendsJuly 2025 Pullbacks & Consistent Profit Focused Trading Strategies - newsyoung.net
How to forecast Affimed N.V. trends using time seriesPortfolio Value Summary & AI Enhanced Market Trend Forecasts - Newser
Price Action Confirms Reversal in Affimed N.V. TrendJuly 2025 Pullbacks & Long-Term Investment Growth Plans - beatles.ru
Using RSI to spot recovery in Affimed N.V.July 2025 Summary & Technical Pattern Based Buy Signals - Newser
Sector ETF Data Correlates with Strength in Affimed N.V.Weekly Trade Report & Capital Protection Trade Alerts - newsyoung.net
Order Book Volume Tilts Bullish on Affimed N.V.Gap Down & Daily Entry Point Alerts - beatles.ru
Affimed N V Stock (AFMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):